Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer

NCT ID: NCT04729543 Phase: PHASE1 / PHASE2 Sponsor: Erasmus Medical Center Status: Recruiting

SUMMARY

Single-centre, first-in-man phase I/II trial to demonstrate safety and efficacy of MAGE-C2/HLA-A2 TCR T cells (MC2 TCR T cells) in advanced melanoma (MEL) and head-and-neck carcinoma (HNSCC).

KEY ELIGIBILITY CRITERIA

- 1. Written informed consent;
- 2. Age e 18 years;
- 3. One of the following three malignancies:
- * Previously treated for unresectable or metastatic cutaneous or mucosal melanoma for whom no standard treatment is available (anymore);
- * Metastatic uveal melanoma, progressing after standard of care therapy, if available;
- * R/M HSNCC for whom no standard treatment is available anymore;
- 4. Patients must be HLA-A2*0201 positive;
- 5. Primary tumor and/or metastasis (archival or fresh biopsy) is positive for MC2 (\>5% of tumor cells) according to immunohisto-chemistry;
- 6. Measurable disease according to RECIST v1.1;
- 7. At least one lesion, suitable for sequential mandatory tumor biopsies;

ENROLLMENT CONTACT

A.A.M. van der Veldt, MD, PhD
Erasmus Medical Center
Rotterdam, Netherlands
Phone: +31 107041754
Email: a.vanderveldt@erasmusmc.nl

Total sites: 1 | 1 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT04729543) and public sources. Generated by FindMyCure.ai.